TSHA-120
Giant Axonal Neuropathy (GAN)
Key Facts
About Taysha Gene Therapies
Taysha Gene Therapies is dedicated to eradicating monogenic CNS diseases through intrathecal delivery of gene therapies. The company has built a robust pipeline leveraging academic partnerships, most notably with UT Southwestern's Gene Therapy Program, and has advanced multiple candidates into clinical development. Following a strategic refocusing in 2023, Taysha is prioritizing its most promising assets, TSHA-102 for Rett syndrome and TSHA-120 for GAN, while seeking partnerships for earlier-stage programs. Its mission centers on addressing the high unmet need in rare neurological diseases with single-administration curative potential.
View full company profile